Literature DB >> 26846589

First-trimester screening with specific algorithms for early- and late-onset fetal growth restriction.

F Crovetto1,2, S Triunfo1, F Crispi1, V Rodriguez-Sureda3, E Roma4, C Dominguez3, E Gratacos1, F Figueras1.   

Abstract

OBJECTIVE: To develop optimal first-trimester algorithms for the prediction of early and late fetal growth restriction (FGR).
METHODS: This was a prospective cohort study of singleton pregnancies undergoing first-trimester screening. FGR was defined as an ultrasound estimated fetal weight < 10(th) percentile plus Doppler abnormalities or a birth weight < 3(rd) percentile. Logistic regression-based predictive models were developed for predicting early and late FGR (cut-off: delivery at 34 weeks). The model included the a-priori risk (maternal characteristics), mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1).
RESULTS: Of the 9150 pregnancies included, 462 (5%) fetuses were growth restricted: 59 (0.6%) early and 403 (4.4%) late. Significant contributions to the prediction of early FGR were provided by black ethnicity, chronic hypertension, previous FGR, MAP, UtA-PI, PlGF and sFlt-1. The model achieved an overall detection rate (DR) of 86.4% for a 10% false-positive rate (area under the receiver-operating characteristics curve (AUC): 0.93 (95% CI, 0.87-0.98)). The DR was 94.7% for FGR with pre-eclampsia (PE) (64% of cases) and 71.4% for FGR without PE (36% of cases). For late FGR, significant contributions were provided by chronic hypertension, autoimmune disease, previous FGR, smoking status, nulliparity, MAP, UtA-PI, PlGF and sFlt-1. The model achieved a DR of 65.8% for a 10% false-positive rate (AUC: 0.76 (95% CI, 0.73-0.80)). The DR was 70.2% for FGR with PE (12% of cases) and 63.5% for FGR without PE (88% of cases).
CONCLUSIONS: The optimal screening algorithm was different for early vs late FGR, supporting the concept that screening for FGR is better performed separately for the two clinical forms.
Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd. Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  early fetal growth restriction; fetal growth restriction; first-trimester screening; late fetal growth restriction; placental growth factor; soluble fms-like tyrosine kinase-1

Mesh:

Substances:

Year:  2016        PMID: 26846589     DOI: 10.1002/uog.15879

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  10 in total

1.  Can Fetal Growth Velocity and First Trimester Maternal Biomarkers Improve the Prediction of Small-for-Gestational Age and Adverse Neonatal Outcome?

Authors:  Manouk L E Hendrix; Judith A P Bons; Roy R G Snellings; Otto Bekers; Sander M J van Kuijk; Marc E A Spaanderman; Salwan Al-Nasiry
Journal:  Fetal Diagn Ther       Date:  2019-05-08       Impact factor: 2.587

2.  A Low Cerebroplacental Ratio at 20-24 Weeks of Gestation Can Predict Reduced Fetal Size Later in Pregnancy or at Birth.

Authors:  Edgar Hernandez-Andrade; Eli Maymon; Offer Erez; Homam Saker; Suchaya Luewan; Maynor Garcia; Hyunyoung Ahn; Adi L Tarca; Bogdan Done; Steven J Korzeniewski; Sonia S Hassan; Roberto Romero
Journal:  Fetal Diagn Ther       Date:  2017-09-20       Impact factor: 2.587

3.  Cell-Free DNA (cfDNA) Fetal Fraction in Early- and Late-Onset Fetal Growth Restriction.

Authors:  Danila Morano; Stefania Rossi; Cristina Lapucci; Maria Carla Pittalis; Antonio Farina
Journal:  Mol Diagn Ther       Date:  2018-10       Impact factor: 4.074

4.  Prediction of Small for Gestational Age Infants in Healthy Nulliparous Women Using Clinical and Ultrasound Risk Factors Combined with Early Pregnancy Biomarkers.

Authors:  Lesley M E McCowan; John M D Thompson; Rennae S Taylor; Philip N Baker; Robyn A North; Lucilla Poston; Claire T Roberts; Nigel A B Simpson; James J Walker; Jenny Myers; Louise C Kenny
Journal:  PLoS One       Date:  2017-01-09       Impact factor: 3.240

5.  Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks' gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study.

Authors:  Teresa M MacDonald; Chuong Tran; Tu'uhevaha J Kaitu'u-Lino; Shaun P Brennecke; Richard J Hiscock; Lisa Hui; Kirsten M Dane; Anna L Middleton; Ping Cannon; Susan P Walker; Stephen Tong
Journal:  BMC Pregnancy Childbirth       Date:  2018-08-31       Impact factor: 3.007

6.  The prediction of early preeclampsia: Results from a longitudinal proteomics study.

Authors:  Adi L Tarca; Roberto Romero; Neta Benshalom-Tirosh; Nandor Gabor Than; Dereje W Gudicha; Bogdan Done; Percy Pacora; Tinnakorn Chaiworapongsa; Bogdan Panaitescu; Dan Tirosh; Nardhy Gomez-Lopez; Sorin Draghici; Sonia S Hassan; Offer Erez
Journal:  PLoS One       Date:  2019-06-04       Impact factor: 3.240

Review 7.  Intrauterine Growth Restriction: New Insight from the Metabolomic Approach.

Authors:  Elena Priante; Giovanna Verlato; Giuseppe Giordano; Matteo Stocchero; Silvia Visentin; Veronica Mardegan; Eugenio Baraldi
Journal:  Metabolites       Date:  2019-11-06

Review 8.  Fetal growth restriction and stillbirth: Biomarkers for identifying at risk fetuses.

Authors:  Victoria J King; Laura Bennet; Peter R Stone; Alys Clark; Alistair J Gunn; Simerdeep K Dhillon
Journal:  Front Physiol       Date:  2022-08-19       Impact factor: 4.755

9.  First trimester screening of circulating C19MC microRNAs and the evaluation of their potential to predict the onset of preeclampsia and IUGR.

Authors:  Ilona Hromadnikova; Katerina Kotlabova; Katarina Ivankova; Ladislav Krofta
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

Review 10.  Combining Biomarkers to Predict Pregnancy Complications and Redefine Preeclampsia: The Angiogenic-Placental Syndrome.

Authors:  Holger Stepan; Martin Hund; Theresa Andraczek
Journal:  Hypertension       Date:  2020-02-17       Impact factor: 10.190

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.